BRPI0924060A2 - Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, o respectivo preparo e a respectiva aplicacao em terapeuutica com atividaores de hif - Google Patents

Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, o respectivo preparo e a respectiva aplicacao em terapeuutica com atividaores de hif

Info

Publication number: BRPI0924060A2
Authority: BR; Brazil
Prior art keywords: hyphenation; pyrazol; pyridin; derivatives; preparation
Prior art date: 2008-12-29

Application number

BRPI0924060-8A

Other languages

English (en)

Inventor

Jean-Michel Altenburger

Valerie Fossey

Stephane Illiano

Géraldine Manette

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-29

Filing date

2009-12-24

Publication date

2015-07-07

2008-12-29 Priority claimed from FR0807474A external-priority patent/FR2940651B1/fr

2009-08-28 Priority claimed from FR0904092A external-priority patent/FR2949466A1/fr

2009-12-24 Application filed by Sanofi Sa filed Critical Sanofi Sa

2015-07-07 Publication of BRPI0924060A2 publication Critical patent/BRPI0924060A2/pt

2015-09-29 Publication of BRPI0924060A8 publication Critical patent/BRPI0924060A8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Immunology (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Biotechnology (AREA)
Pathology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)

BRPI0924060A 2008-12-29 2009-12-24 derivados de 2-piridin-2-il-pirazol-3(2h)-ona, o respectivo preparo e a respectiva aplicação em terapêutica com ativadores de hif BRPI0924060A8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR0807474A FR2940651B1 (fr)	2008-12-29	2008-12-29	Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique comme activateurs de hif
FR0904092A FR2949466A1 (fr)	2009-08-28	2009-08-28	Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif
PCT/FR2009/052691 WO2010076524A2 (fr)	2008-12-29	2009-12-24	Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif

Publications (2)

Publication Number	Publication Date
BRPI0924060A2 true BRPI0924060A2 (pt)	2015-07-07
BRPI0924060A8 BRPI0924060A8 (pt)	2015-09-29

Family

ID=42008610

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0924060A BRPI0924060A8 (pt)	2008-12-29	2009-12-24	derivados de 2-piridin-2-il-pirazol-3(2h)-ona, o respectivo preparo e a respectiva aplicação em terapêutica com ativadores de hif

Country Status (35)

Country	Link
US (1)	US8541455B2 (pt)
EP (1)	EP2382205B1 (pt)
JP (1)	JP5734870B2 (pt)
KR (1)	KR20110099786A (pt)
CN (1)	CN102333769B (pt)
AR (1)	AR074915A1 (pt)
AU (1)	AU2009334569B2 (pt)
BR (1)	BRPI0924060A8 (pt)
CA (1)	CA2748411A1 (pt)
CL (1)	CL2011001496A1 (pt)
CO (1)	CO6400141A2 (pt)
CR (1)	CR20110361A (pt)
CY (1)	CY1115368T1 (pt)
DK (1)	DK2382205T3 (pt)
EA (1)	EA019591B1 (pt)
EC (1)	ECSP11011155A (pt)
ES (1)	ES2481042T3 (pt)
HR (1)	HRP20140680T1 (pt)
IL (1)	IL213789A (pt)
MA (1)	MA32976B1 (pt)
MX (1)	MX2011007054A (pt)
MY (1)	MY179093A (pt)
NZ (1)	NZ593751A (pt)
PA (1)	PA8856201A1 (pt)
PE (1)	PE20120416A1 (pt)
PL (1)	PL2382205T3 (pt)
PT (1)	PT2382205E (pt)
SG (1)	SG172803A1 (pt)
SI (1)	SI2382205T1 (pt)
SM (1)	SMT201400097B (pt)
TN (1)	TN2011000267A1 (pt)
TW (1)	TWI482763B (pt)
UY (1)	UY32369A (pt)
WO (1)	WO2010076524A2 (pt)
ZA (1)	ZA201104783B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2382215T1 (sl)	2008-12-29	2020-06-30	Sanofi	Derivati 2-piridin-2-il-pirazol-3(2H)-ona, njihova priprava in njihova terapevtska uporaba
WO2012133783A1 (ja) *	2011-03-31	2012-10-04	キッセイ薬品工業株式会社	ベンジルピラゾール誘導体の製造方法およびその製造中間体
HK1204621A1 (en) *	2012-03-30	2015-11-27	Daiichi Sankyo Company, Limited	4-alkanoylamino-3-pyrazolone derivative
SI2978752T1 (en)	2013-03-29	2018-04-30	Takeda Pharmaceutical Company Limited	6- (5-Hydroxy-1H-pyrazol-1-yl) nicotinamide derivatives and their use as inhibitors of PHD
DE102016223133A1 (de)	2016-11-23	2018-05-24	Deere & Company	Geschwindigkeitskontrolle einer Erntemaschine
BR112022018878A2 (pt) *	2020-03-20	2022-11-29	Akebia Therapeutics Inc	Compostos, composição farmacêutica e método para tratar uma doença mediada por atividade de phd

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4023488A1 (de) *	1990-07-24	1992-01-30	Bayer Ag	1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide
US5750088A (en)	1993-03-30	1998-05-12	The Dupont Merck Pharmaceutical Company	Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
US7226941B2 (en)	2003-06-30	2007-06-05	Hif Bio, Inc.	Compound for treating angiogenesis
DE102005019712A1 (de) *	2005-04-28	2006-11-09	Bayer Healthcare Ag	Dipyridyl-dihydropyrazolone und ihre Verwendung
TW200808793A (en)	2006-03-07	2008-02-16	Smithkline Beecham Corp	Prolyl hydroxylase inhibitors
CA2666603C (en)	2006-10-16	2013-08-06	Pfizer Products Inc.	Therapeutic pyrazolyl thienopyridines and uses thereof for treating tgf.beta. mediated conditions
DE102006050516A1 (de) *	2006-10-26	2008-04-30	Bayer Healthcare Ag	Substituierte Dihydropyrazolone und ihre Verwendung
RU2009146851A (ru)	2007-05-18	2011-06-27	Байер Шеринг Фарма Акциенгезельшафт (DE)	Гетероарил-замещенные пиразольные производные, которые могут использоваться для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом

2009
- 2009-12-24 SI SI200930983T patent/SI2382205T1/sl unknown
- 2009-12-24 MX MX2011007054A patent/MX2011007054A/es active IP Right Grant
- 2009-12-24 BR BRPI0924060A patent/BRPI0924060A8/pt not_active IP Right Cessation
- 2009-12-24 ES ES09805789.6T patent/ES2481042T3/es active Active
- 2009-12-24 CN CN200980157590.6A patent/CN102333769B/zh not_active Expired - Fee Related
- 2009-12-24 PL PL09805789T patent/PL2382205T3/pl unknown
- 2009-12-24 NZ NZ593751A patent/NZ593751A/xx not_active IP Right Cessation
- 2009-12-24 EP EP09805789.6A patent/EP2382205B1/fr active Active
- 2009-12-24 CA CA2748411A patent/CA2748411A1/fr not_active Abandoned
- 2009-12-24 DK DK09805789.6T patent/DK2382205T3/da active
- 2009-12-24 HR HRP20140680AT patent/HRP20140680T1/hr unknown
- 2009-12-24 EA EA201170899A patent/EA019591B1/ru not_active IP Right Cessation
- 2009-12-24 JP JP2011542886A patent/JP5734870B2/ja not_active Expired - Fee Related
- 2009-12-24 WO PCT/FR2009/052691 patent/WO2010076524A2/fr active Application Filing
- 2009-12-24 PT PT98057896T patent/PT2382205E/pt unknown
- 2009-12-24 PE PE2011001292A patent/PE20120416A1/es not_active Application Discontinuation
- 2009-12-24 SG SG2011047503A patent/SG172803A1/en unknown
- 2009-12-24 MY MYPI2011003012A patent/MY179093A/en unknown
- 2009-12-24 AU AU2009334569A patent/AU2009334569B2/en not_active Ceased
- 2009-12-24 MA MA34027A patent/MA32976B1/fr unknown
- 2009-12-24 KR KR1020117017676A patent/KR20110099786A/ko not_active Abandoned
- 2009-12-28 AR ARP090105126A patent/AR074915A1/es unknown
- 2009-12-28 TW TW098145336A patent/TWI482763B/zh not_active IP Right Cessation
- 2009-12-29 UY UY0001032369A patent/UY32369A/es not_active Application Discontinuation
- 2009-12-29 PA PA20098856201A patent/PA8856201A1/es unknown
2011
- 2011-05-24 TN TN2011000267A patent/TN2011000267A1/fr unknown
- 2011-06-17 CL CL2011001496A patent/CL2011001496A1/es unknown
- 2011-06-22 EC EC2011011155A patent/ECSP11011155A/es unknown
- 2011-06-23 CR CR20110361A patent/CR20110361A/es unknown
- 2011-06-27 IL IL213789A patent/IL213789A/en not_active IP Right Cessation
- 2011-06-28 ZA ZA2011/04783A patent/ZA201104783B/en unknown
- 2011-06-29 US US13/172,305 patent/US8541455B2/en not_active Expired - Fee Related
- 2011-06-29 CO CO11081326A patent/CO6400141A2/es active IP Right Grant
2014
- 2014-07-22 SM SM201400097T patent/SMT201400097B/xx unknown
- 2014-07-23 CY CY20141100553T patent/CY1115368T1/el unknown

Also Published As

Publication number	Publication date
CO6400141A2 (es)	2012-03-15
WO2010076524A2 (fr)	2010-07-08
MX2011007054A (es)	2011-11-29
MY179093A (en)	2020-10-27
PT2382205E (pt)	2014-07-28
US8541455B2 (en)	2013-09-24
WO2010076524A3 (fr)	2010-08-26
CN102333769A (zh)	2012-01-25
TN2011000267A1 (fr)	2012-12-17
JP5734870B2 (ja)	2015-06-17
ECSP11011155A (es)	2011-07-29
DK2382205T3 (da)	2014-07-28
MA32976B1 (fr)	2012-01-02
IL213789A0 (en)	2011-07-31
PL2382205T3 (pl)	2014-09-30
PE20120416A1 (es)	2012-05-08
EP2382205A2 (fr)	2011-11-02
AR074915A1 (es)	2011-02-23
AU2009334569A1 (en)	2011-07-21
EA201170899A1 (ru)	2012-02-28
SG172803A1 (en)	2011-08-29
AU2009334569B2 (en)	2016-02-25
KR20110099786A (ko)	2011-09-08
SI2382205T1 (sl)	2014-08-29
NZ593751A (en)	2013-08-30
CN102333769B (zh)	2014-08-27
HRP20140680T1 (hr)	2014-10-10
PA8856201A1 (es)	2010-07-27
US20110294788A1 (en)	2011-12-01
IL213789A (en)	2014-11-30
CY1115368T1 (el)	2017-01-04
CR20110361A (es)	2011-09-20
BRPI0924060A8 (pt)	2015-09-29
UY32369A (es)	2010-07-30
ES2481042T3 (es)	2014-07-29
CA2748411A1 (fr)	2010-07-08
SMT201400097B (it)	2014-09-08
EP2382205B1 (fr)	2014-04-23
JP2012513976A (ja)	2012-06-21
EA019591B1 (ru)	2014-04-30
ZA201104783B (en)	2012-09-26
TWI482763B (zh)	2015-05-01
CL2011001496A1 (es)	2011-10-28
TW201028391A (en)	2010-08-01

Publication	Publication Date	Title
BRPI0810440A2 (pt)	2014-10-14	Derivados de triazolopiridina-carboxamidas e triazolopirimidina-carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0907381A2 (pt)	2015-07-14	Derivados de carboxamidas azabicíclicos, o respectivo preparo e a respectiva aplicação em terapêutica.
BRPI0810412A2 (pt)	2014-10-14	Derivados de triazolo piridina-carboxamidas e triazolo pirimidina - carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI1012857A2 (pt)	2019-09-24	derivados de ciclopenta[c]pirrol-2-carboxilatos, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0906567A2 (pt)	2015-07-07	Derivados de ureia de tetra-hidroquinoxalina, o respectivo preparo e a respectiva aplicação em terapêutica j
IL204663A0 (en)	2010-11-30	Nicotinamide derivatives, preparastion thereof and therapeutic use thereof
BRPI0907439A2 (pt)	2015-08-04	Derivado de carboxamidas azabiciclicos, o respectivo preparo e a respectiva aplicação em terapêutica
IL192281A0 (en)	2008-12-29	Morpholino pyrimidine derivatives and their use in therapy
BRPI1008045A2 (pt)	2016-03-15	derivados de aminotetralina, composições farmacêuticas contendo-os, e seu uso em terapia
BRPI0908999A2 (pt)	2015-08-04	Derivados poli-substituídos de 2-aril-6-imidazo[1,2-a]piridinas, o respectivo preparo e respectiva aplicação em terapêutica
IL213168A0 (en)	2011-07-31	1,2,4-oxadiazole derivatives and their therapeutic use
BRPI0915438A2 (pt)	2015-11-10	derivados de piridino-piridinonas, o respectivo preparo e a respectiva aplicação em terapêutica.
ZA201001189B (en)	2010-11-24	Treatments using vitamin k analogues and derivatives
BRPI0810430A2 (pt)	2014-10-14	Derivados de triazolo piridina - carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica
DK2158201T3 (da)	2011-08-01	Derivater af 7-alkynyl-1,8-naphthyridon, fremgangsmåde til fremstilling deraf og anvendelse deraf i terapi
BRPI1013553A2 (pt)	2016-04-12	derivados de nicotinamida, o respectivo preparo e a respectiva aplicação em terapêutica como anticancerígenos
BRPI0924060A2 (pt)	2015-07-07	Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, o respectivo preparo e a respectiva aplicacao em terapeuutica com atividaores de hif
BRPI0923875A2 (pt)	2015-07-21	Derivados de 2-piridin-2-il-pirazol-3 (2h)-ona, o respectivo preparo e a respectiva aplicação terapêutica.
ZA201104100B (en)	2012-11-28	Dimeric avermectin and milbemycin derivatives
BRPI0907578A2 (pt)	2019-09-24	derivados de 3-aminoalquil-1,3-di-hidro-2h-indol-2-ona, o respectivo preparo e a respectiva aplicação em terapêutica
BR112012000104A2 (pt)	2016-03-15	derivados de pirazóis, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0912133A2 (pt)	2015-11-03	artigo resitente á penetração, e, uso do mesmo.
BRPI0923182A2 (pt)	2019-09-24	derivados de 6-cicloamino-2,3-di-piridinil-imidazo[1,2-b]piridazina, o respectivo preparo e a respectivo preparo e a respectiva aplicação terapêutica
BRPI0714318A2 (pt)	2014-06-24	Utilização de 2-benzoil-imidazopiridinas em terapêutica
IL195207A0 (en)	2009-08-03	Aryl-and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their application in therapeutics

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-10-23	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2018-10-30	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 9A ANUIDADE.
2019-03-19	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.